GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Sloan Ratio %

Aclarion (Aclarion) Sloan Ratio % : -29.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Aclarion's Sloan Ratio for the quarter that ended in Mar. 2024 was -29.00%.

Warning Sign:

When sloan ratio (-46.5)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Aclarion has a Sloan Ratio of -29.00%, indicating earnings are more likely to be made up of accruals.


Aclarion Sloan Ratio % Historical Data

The historical data trend for Aclarion's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Sloan Ratio % Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
29.30 -206.04 -129.59 -65.59 -46.50

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.00 -43.51 -26.44 -46.46 -29.00

Competitive Comparison of Aclarion's Sloan Ratio %

For the Health Information Services subindustry, Aclarion's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclarion's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Aclarion's Sloan Ratio % falls into.



Aclarion Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Aclarion's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-4.911--3.647
--0.12)/2.46
=-46.50%

Aclarion's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-6.127--4.874
--0.172)/3.727
=-29.00%

Aclarion's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -1.465 (Jun. 2023 ) + -0.998 (Sep. 2023 ) + -1.265 (Dec. 2023 ) + -2.399 (Mar. 2024 ) = $-6.13 Mil.
Aclarion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.948 (Jun. 2023 ) + -0.953 (Sep. 2023 ) + -0.734 (Dec. 2023 ) + -2.239 (Mar. 2024 ) = $-4.87 Mil.
Aclarion's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.061 (Jun. 2023 ) + -0.013 (Sep. 2023 ) + -0.034 (Dec. 2023 ) + -0.064 (Mar. 2024 ) = $-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACON) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Aclarion has a Sloan Ratio of -29.00%, indicating earnings are more likely to be made up of accruals.


Aclarion Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Aclarion's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion (Aclarion) Business Description

Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404